
==== Front
Adv UrolAdv UrolAUAdvances in Urology1687-63691687-6377Hindawi Publishing Corporation 10.1155/2016/6345816CorrigendumCorrigendum to “HDR Brachytherapy in the Management of High-Risk Prostate Cancer” http://orcid.org/0000-0001-7747-0412Masson Susan 
1
Persad Raj 
2

*
Bahl Amit 
1
1Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol BS2 8ED, UK2Department of Urology, University Hospitals Bristol NHS Foundation Trust, Bristol BS2 8HW, UK*Raj Persad: raj.persad@uhbristol.nhs.uk2016 21 11 2016 2016 634581618 9 2016 26 9 2016 Copyright © 2016 Susan Masson et al.2016This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
==== Body
In the article titled “HDR Brachytherapy in the Management of High-Risk Prostate Cancer” [1], there was an error in Table 2, which should be corrected as follows: For Hoskin et al. [32], the dose should read 35.75 Gy in 13 fractions EBRT, not 55 Gy in 20 fractions EBRT.

Table 2 Estimated equivalent doses (2 Gy per fraction) for published HDR schedules using the EQD2 formula, assuming α/β for prostate cancer of 1.5 Gy [19].

Author	Schedule	EQD2 prostate (α/β 1.5 Gy)	
Galalae et al. [36]	50 Gy WPRT, 40 Gy Prostate EBRT, 2 fractions HDR (9 Gy per fraction)	94 Gy	
Åström et al. [30]	50 Gy in 25 fractions EBRT, 2 fractions HDR (10 Gy per fraction)	115.7 Gy	
Martinez et al. [28]	46 Gy in 23 fractions EBRT, 2 fractions HDR (11.5 Gy per fraction)	131.4 Gy	
Hoskin et al. [32]	35.75 Gy in 13 fractions EBRT, 2 fractions HDR (8.5 Gy per fraction)	92.0 Gy
==== Refs
1 Masson S.  Persad R.  Bahl A.   HDR brachytherapy in the management of high-risk prostate cancer Advances in Urology  2012 2012 6 980841 10.1155/2012/980841 2-s2.0-84858269115
